GLP-1 Obesity Drugs Show Potential to Extend Lifespan in Older Female Mice
A recent study published in Nature on September 2, 2026, explores the potential anti-aging effects of GLP-1 obesity drugs, specifically semaglutide, which is commonly administered for weight management. This research indicates that older female mice receiving semaglutide lived longer than their untreated counterparts, with a median lifespan of 834 days compared to 742 days for the control group. The study also observed improvements in various health markers, including coordination and muscle function, suggesting that these drugs may offer benefits beyond mere weight loss.
The study involved 20-month-old female mice, roughly equivalent to 60-year-old humans, and aimed to determine whether the longevity effects were due to reduced calorie intake. Mice treated with semaglutide self-reduced their calorie intake by 24%, prompting researchers to investigate if this calorie restriction was the sole factor contributing to their extended lifespan. Interestingly, when a separate group of untreated mice was placed on a diet matching the calorie intake of the semaglutide group, both groups exhibited similar longevity outcomes. However, the semaglutide-treated mice outperformed the diet group in cognitive tests, such as spatial memory, indicating that the drug may have additional benefits that are not solely linked to calorie reduction.
While the findings are promising, experts caution that they are still preliminary. Michael Corley, a scientist specializing in aging at the University of California, San Diego, emphasized the rigorous nature of the study but noted the need for further research to establish whether GLP-1 drugs can be effectively prescribed for longevity in humans. Danica Chen, a co-author of the study from the University of California, Berkeley, highlighted the importance of understanding the mechanisms behind the observed benefits, as the exact drivers remain unclear. As clinical trials are initiated to explore these effects in humans, the implications of this research could significantly impact the future of aging therapies and our understanding of the relationship between obesity treatment and lifespan.




